ARTICLE SUMMARY:
ReCor Medical is conducting clinical trials with its Paradise ultrasound renal denervation system and is moving closer to a US PMA filing, a goal it hopes to reach in 2022. We speak with President and CEO Andrew Weiss about the company’s role in the rebirth of RDN.
While Medtronic plc continues to progress with its radiofrequency renal denervation (RDN) technology, the company’s primary competitor, ReCor Medical Inc. (which merged with Otsuka Holdings in 2018), is pinning its RDN hopes on the Paradise system, a balloon catheter device that utilizes ultrasound energy to ablate the sympathetic nerves that reside in the renal arteries.
